Literature DB >> 17010628

Development of acetylated HDD kit for preparation of 188Re-HDD/lipiodol.

Yun-Sang Lee1, Jae Min Jeong, Young Joo Kim, Young Soo Chang, Hak Jeong Lee, Miwon Son, Jung Woo Lee, Heung Sik Yoon, Won Jun Kang, Dong Soo Lee, June-Key Chung, Myung Chul Lee, Young-Ger Suh.   

Abstract

A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol ((188)Re-HDD/lipiodol) is in clinical study for liver cancer therapy. However, formulation of it is difficult due to highly active and unstable sulfhydryl groups. We produced new kits using diacetylated HDD (AHDD), in which sulfhydryl groups are protected. We found that AHDD kit can replace HDD kit due to an increased stability for formulation, the better radiolabeling efficiency (78%) and the equivalent biodistribution pattern in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010628     DOI: 10.1016/j.apradiso.2006.07.008

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  3 in total

Review 1.  KSNM60: The History of Radiopharmaceutical Sciences in Korea.

Authors:  Ran Ji Yoo; Yun-Sang Lee; Kyo Chul Lee; Dong Wook Kim; Dong-Yeon Kim; Yearn Seong Choe; Jae Min Jeong
Journal:  Nucl Med Mol Imaging       Date:  2022-04-05

2.  Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans.

Authors:  Pedro L Esquinas; Ajit Shinto; Koramadai K Kamaleshwaran; Jephy Joseph; Anna Celler
Journal:  EJNMMI Phys       Date:  2018-12-07

Review 3.  Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres.

Authors:  C Bouvry; X Palard; J Edeline; V Ardisson; P Loyer; E Garin; N Lepareur
Journal:  Biomed Res Int       Date:  2018-12-31       Impact factor: 3.246

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.